Immunoconjugates as an Efficient Platform for Drug Delivery: A Resurgence of Natural Products in Targeted Antitumor Therapy DOI Creative Commons
Rositsa Mihaylova, Denitsa Momekova,

Viktoria Elincheva

et al.

Pharmaceuticals, Journal Year: 2024, Volume and Issue: 17(12), P. 1701 - 1701

Published: Dec. 17, 2024

The present review provides a detailed and comprehensive discussion on antibody–drug conjugates (ADCs) as an evolving new modality in the current therapeutic landscape of malignant diseases. principle concepts targeted delivery highly toxic agents forsaken stand-alone drugs are examined detail, along with biochemical technological tools for their successful implementation. An extensive analysis ADCs’ major components is conducted parallel function impact stability, efficacy, safety, resistance profiles immunoconjugates. scope article covers classes currently validated natural compounds used payloads, emphasis structural mechanistic features, origin, distribution. Future perspectives design thoroughly explored, addressing inherent or emerging challenges limitations. survey also overview molecular rationale active tumor targeting ADC-based platforms, exploring cellular biology clinical relevance markers “homing” mechanism both hematological solid malignancies.

Language: Английский

Diverse Roles of Antibodies in Antibody–Drug Conjugates DOI Creative Commons
Aiko Yamaguchi,

H. Charles Manning

Pharmaceuticals, Journal Year: 2025, Volume and Issue: 18(2), P. 180 - 180

Published: Jan. 29, 2025

The emergence of antibody–drug conjugates (ADCs) has transformed the treatment landscape a variety cancers. ADCs typically consist three main components: monoclonal antibody, chemical linker, and cytotoxic payload. These integrated therapeutic modalities harness benefits each component to provide response that cannot be achieved by conventional chemotherapy. Antibodies play roles in determining tumor specificity through target-mediated uptake, prolonging circulation half-life payloads, providing additional mechanisms action inherent original thus significantly contributing overall performance ADCs. However, have unique safety concerns, such as drug-induced adverse events related uptake ADC normal tissues (so-called “on-target, off-tumor toxicity”) platform toxicity, which are partially derived from limited antibodies. Identifying suitable target antigens impacts clinical success requires careful consideration, given multifaceted aspects this modality. This review briefly summarizes representative antibodies efficacy Key considerations for selecting cell surface therapy also highlighted.

Language: Английский

Citations

0
Challenges and opportunities in single-domain antibody-based tumor immunotherapy DOI
Xiaozhi Xi,

Guo Shu-hua,

Yuchao Gu

et al.

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Journal Year: 2025, Volume and Issue: unknown, P. 189284 - 189284

Published: Feb. 1, 2025

Language: Английский

Citations

0
New Strategy for the design and cloning of Novel Humanized Biparatopic Anti-CD52 Nanobodies: Tools for Targeted Drug Delivery and Therapeutic Approaches DOI
Mohammad Heidari, Mehri Khatami,

Amir Soltanzade

et al.

Biochemical Engineering Journal, Journal Year: 2025, Volume and Issue: unknown, P. 109736 - 109736

Published: March 1, 2025

Language: Английский

Citations

0
Immunoconjugates as an Efficient Platform for Drug Delivery: A Resurgence of Natural Products in Targeted Antitumor Therapy DOI Creative Commons
Rositsa Mihaylova, Denitsa Momekova,

Viktoria Elincheva

et al.

Pharmaceuticals, Journal Year: 2024, Volume and Issue: 17(12), P. 1701 - 1701

Published: Dec. 17, 2024

The present review provides a detailed and comprehensive discussion on antibody–drug conjugates (ADCs) as an evolving new modality in the current therapeutic landscape of malignant diseases. principle concepts targeted delivery highly toxic agents forsaken stand-alone drugs are examined detail, along with biochemical technological tools for their successful implementation. An extensive analysis ADCs’ major components is conducted parallel function impact stability, efficacy, safety, resistance profiles immunoconjugates. scope article covers classes currently validated natural compounds used payloads, emphasis structural mechanistic features, origin, distribution. Future perspectives design thoroughly explored, addressing inherent or emerging challenges limitations. survey also overview molecular rationale active tumor targeting ADC-based platforms, exploring cellular biology clinical relevance markers “homing” mechanism both hematological solid malignancies.

Language: Английский

Citations

1